Market Overview

Recap: Intra-Cellular Therapies Q3 Earnings



Shares of Intra-Cellular Therapies (NASDAQ:ITCI) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 25.40% year over year to ($0.79), which beat the estimate of ($1.00).

Revenue of $7,369,000 higher by 0.00% year over year, which beat the estimate of $5,860,000.

Looking Ahead

Intra-Cellular Therapies hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL:


Company's 52-week high was at $43.56

52-week low: $8.51

Price action over last quarter: Up 29.21%

Company Overview

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.


Related Articles (ITCI)

View Comments and Join the Discussion!

Posted-In: Earnings News